Profile data is unavailable for this security.
About the company
Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.
- Revenue in AUD (TTM)1.28m
- Net income in AUD-4.98m
- Incorporated2016
- Employees--
- LocationNeurotech International LtdSuite 5 CPC, 145 Stirling HighwayNEDLANDS 6009AustraliaAUS
- Phone+61 89389-3130
- Fax+61 89321-5932
- Websitehttps://neurotechinternational.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDT Australia Limited | 10.36m | -6.55m | 47.25m | 156.00 | -- | 1.72 | -- | 4.56 | -0.0215 | -0.0215 | 0.0341 | 0.0639 | 0.3741 | 2.39 | 3.51 | -- | -23.64 | -9.87 | -26.41 | -11.57 | 76.38 | 84.42 | -63.19 | -24.94 | 2.81 | -- | 0.0907 | -- | -42.03 | -11.97 | -632.59 | -- | -26.04 | -- |
| Cynata Therapeutics Ltd | 436.25k | -13.65m | 48.50m | 0.00 | -- | 3.95 | -- | 111.18 | -0.0873 | -0.0873 | 0.0027 | 0.0683 | 0.0257 | -- | 4.26 | -- | -80.33 | -38.07 | -87.15 | -41.10 | -- | -- | -3,127.93 | -513.73 | -- | -- | 0.00 | -- | -94.96 | 19.81 | -162.20 | -- | -- | -- |
| Anteotech Ltd | 526.75k | -11.46m | 51.83m | 40.00 | -- | 9.71 | -- | 98.40 | -0.0056 | -0.0056 | 0.0003 | 0.0022 | 0.0552 | -- | 2.62 | -- | -120.11 | -68.55 | -145.22 | -75.44 | -- | -- | -2,176.15 | -1,432.10 | -- | -- | 0.1729 | -- | -46.65 | 11.41 | -18.08 | -- | 25.84 | -- |
| LTR Pharma Ltd | -100.00bn | -100.00bn | 57.03m | -- | -- | 17.98 | -- | -- | -- | -- | -- | 0.0451 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -41.65 | -- | -- | -- |
| Inoviq Ltd | 751.54k | -6.51m | 58.04m | 85.00 | -- | 3.02 | -- | 77.22 | -0.0708 | -0.0708 | 0.0082 | 0.182 | 0.0339 | 2.10 | 0.873 | -- | -29.33 | -47.68 | -32.18 | -50.76 | 95.07 | -- | -866.27 | -2,527.82 | 4.93 | -- | 0.0332 | -- | 119.59 | 153.31 | 50.71 | -- | -- | -- |
| Percheron Therapeutics Ltd | 624.51k | -10.85m | 72.12m | 8.00 | -- | 4.38 | -- | 115.49 | -0.0157 | -0.0157 | 0.0009 | 0.0182 | 0.0328 | -- | 0.3224 | -- | -56.94 | -72.09 | -66.58 | -81.73 | -- | -- | -1,737.37 | -6,558.90 | -- | -- | 0.001 | -- | 1,026.16 | 72.03 | -95.81 | -- | -- | -- |
| Neurotech International Ltd | 1.28m | -4.98m | 75.29m | -- | -- | 13.76 | -- | 58.94 | -0.0058 | -0.0058 | 0.0015 | 0.0054 | 0.1826 | -0.1149 | 5.67 | -- | -71.23 | -197.33 | -74.66 | -255.24 | 100.07 | 79.57 | -390.03 | -1,043.88 | 18.35 | -- | 0.00 | -- | 106.22 | 83.24 | -131.75 | -- | -- | -- |
| Paradigm Biopharmaceuticals Ltd | 8.67m | -69.00m | 97.94m | -- | -- | 2.91 | -- | 11.30 | -0.2296 | -0.2296 | 0.0288 | 0.0962 | 0.1298 | -- | 2.25 | -- | -103.34 | -40.96 | -127.58 | -44.13 | 99.87 | -- | -796.30 | -466.85 | -- | -348.76 | 0.0085 | -- | 7.58 | 25.42 | -32.26 | -- | -- | -- |
| Argenica Therapeutics Ltd | 92.21k | -4.67m | 101.43m | -- | -- | 12.33 | -- | 1,100.04 | -0.0511 | -0.0511 | 0.001 | 0.0665 | 0.0109 | -- | 0.6384 | -- | -55.31 | -- | -69.00 | -- | -- | -- | -5,067.62 | -- | -- | -6,663.20 | 0.00 | -- | 2,340.00 | -- | -17.71 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Merchant Funds Management Pty Ltd.as of 18 Mar 2024 | 65.34m | 6.42% |
